Literature DB >> 12654687

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays.

Gloria M González1, Rolando Tijerina, Laura K Najvar, Rosie Bocanegra, Michael G Rinaldi, David Loebenberg, John R Graybill.   

Abstract

Thirty isolates of Pseudallescheria boydii were tested to compare the in vitro activity of posaconazole with those of fluconazole and itraconazole, using NCCLS methods. Posaconazole was evaluated in an immunosuppressed mouse model of disseminated pseudallescheriasis. Posaconazole was more effective than itraconazole and as effective as fluconazole in preventing death and significantly reducing the CFU of P. boydii from tissues.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12654687      PMCID： PMC152491          DOI： 10.1128/AAC.47.4.1436-1438.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Antifungal prophylaxis for solid organ transplant recipients: seeking clarity amidst controversy.

Authors:  N Singh
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

2.  Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy.

Authors:  P Muñoz; M Marín; P Tornero; P Martín Rabadán; M Rodríguez-Creixéms; E Bouza
Journal:  Clin Infect Dis       Date:  2000-12       Impact factor: 9.079

3.  Efficacy of SCH56592 in a rabbit model of invasive aspergillosis.

Authors:  W R Kirkpatrick; R K McAtee; A W Fothergill; D Loebenberg; M G Rinaldi; T F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

4.  Case report. Atypical cutaneous pseudallescheriosis refractory to antifungal agents.

Authors:  G Ginter; B Petutschnig; G Pierer; H P Soyer; S Reischle; T Kern; S de Hoog
Journal:  Mycoses       Date:  1999       Impact factor: 4.377

5.  Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole.

Authors:  S L Goldberg; D J Geha; W F Marshall; D J Inwards; H C Hoagland
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

6.  Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.

Authors:  M A Pfaller; S Messer; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Pseudallescheria boydii infections treated with ketoconazole. Clinical evaluations of seven patients and in vitro susceptibility results.

Authors:  J N Galgiani; D A Stevens; J R Graybill; D L Stevens; A J Tillinghast; H B Levine
Journal:  Chest       Date:  1984-08       Impact factor: 9.410

8.  Experimental murine model of disseminated Pseudallescheria infection.

Authors:  G M González; R Tijerina; L Najvar; M Rinaldi; I T Yeh; J R Graybill
Journal:  Med Mycol       Date:  2002-06       Impact factor: 4.076

9.  In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.

Authors:  J R Perfect; G M Cox; R K Dodge; W A Schell
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

10.  Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies.

Authors:  L I Lutwick; J N Galgiani; R H Johnson; D A Stevens
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965
View more
  11 in total

Review 1.  Pharmacokinetic/pharmacodynamic profile of posaconazole.

Authors:  Yanjun Li; Ursula Theuretzbacher; Cornelius J Clancy; M Hong Nguyen; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2010-06       Impact factor: 6.447

2.  Rapid identification of Pseudallescheria and Scedosporium strains by using rolling circle amplification.

Authors:  Michaela Lackner; Mohammad Javad Najafzadeh; Jiufeng Sun; Qiaoyun Lu; G Sybren de Hoog
Journal:  Appl Environ Microbiol       Date:  2011-11-04       Impact factor: 4.792

3.  Experimental murine scedosporiosis: histopathology and azole treatment.

Authors:  M Mar Rodríguez; F Javier Pastor; Valentina Salas; Enrique Calvo; Emilio Mayayo; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

Review 4.  Posaconazole.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans.

Authors:  M Simitsopoulou; C Gil-Lamaignere; N Avramidis; A Maloukou; S Lekkas; E Havlova; L Kourounaki; D Loebenberg; E Roilides
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

Review 6.  Infections caused by Scedosporium spp.

Authors:  Karoll J Cortez; Emmanuel Roilides; Flavio Quiroz-Telles; Joseph Meletiadis; Charalampos Antachopoulos; Tena Knudsen; Wendy Buchanan; Jeffrey Milanovich; Deanna A Sutton; Annette Fothergill; Michael G Rinaldi; Yvonne R Shea; Theoklis Zaoutis; Shyam Kottilil; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

Review 7.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.

Authors:  John R Graybill; Laura K Najvar; Elizabeth Johnson; Rosie Bocanegra; David Loebenberg
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

Review 9.  Posaconazole: An Update of Its Clinical Use.

Authors:  Simon Leung; Mara N Poulakos; Jade Machin
Journal:  Pharmacy (Basel)       Date:  2015-10-21

10.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.